Neurofibromatose 1 : recommandations de prise en charge
S. Pinson(Hôpital Edouard Herriot), P. Wolkenstein(Université Paris-Est Créteil), J.‐F. Stalder(Centre Hospitalier Universitaire de Nantes), Stanislas Lyonnet(Hôpital Necker-Enfants Malades), S. Barbarot(Hotel Dieu Hospital), J.‐P. Lacour(Centre Hospitalier Universitaire de Nice), François Doz(Institut Curie), Michel Zérah(Hôpital Necker-Enfants Malades), B. Guillot(Université de Montpellier), P. Combemale(Centre Léon Bérard), Diana Rodriguez(Sorbonne Université), Marc Sanson(Centre National de la Recherche Scientifique), Alain Créange(Université Paris-Est Créteil), M. D’Incan(Centre Hospitalier Universitaire de Clermont-Ferrand), Alain Bernheim(Triemli Hospital), J Zeller(Hôpitaux Universitaires Henri-Mondor), C Kalifa(Institut Gustave Roussy), D Teillac-Hamel(Hôpital Necker-Enfants Malades), C Stoll(Hôpital d'Hautepierre), Yves Chaix(Hôpital des Enfants)
Cited by 46
Related Papers
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2.1k
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
|Neuro-Oncology|2020|1.1k
Genome-wide association study identifies five susceptibility loci for glioma
|Nature Genetics|2009|797
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation
|Genetics in Medicine|2021|766
Chronic Infantile Neurological Cutaneous and Articular Syndrome Is Caused by Mutations in CIAS1, a Gene Highly Expressed in Polymorphonuclear Cells and Chondrocytes
|The American Journal of Human Genetics|2002|740